EE254 The Cost-Consequence of Budesonide/Formoterol Plus As-Needed Saba As Treatment for 6-12 Years Old Pediatric Asthma Patients in ChinaBased on Real-World Data
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.553
https://www.valueinhealthjournal.com/article/S1098-3015(24)00668-5/fulltext
Title :
EE254 The Cost-Consequence of Budesonide/Formoterol Plus As-Needed Saba As Treatment for 6-12 Years Old Pediatric Asthma Patients in ChinaBased on Real-World Data
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00668-5&doi=10.1016/j.jval.2024.03.553
First page :
Section Title :
Open access? :
No
Section Order :
10028